AstraZeneca is helping eligible patients pay no more than $35 per month for their inhaled respiratory medicine

Starting June 1, 2024, eligible* patients will pay no more than $35 per month for all inhaled respiratory medicines. If you have questions about this program or your eligibility, please contact +1 (800) 236-9933.

*Terms and conditions apply. Government restrictions exclude people enrolled in federal government insurance programs from co-pay support. If you don’t meet the terms and conditions and cannot afford your medication, you may be eligible for AZ&Me.

We plan to extend our current cap on patient out-of-pocket costs at $35 per month* for our inhaled respiratory medicines containing a novel propellant with near-zero global warming potential, subject to regulatory approvals.

For more than 50 years, AstraZeneca has served respiratory patients by investing in the research and development of the new drug-device combinations, as well as next-generation biologics to address the vast unmet needs of these chronic, often debilitating disease. AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our medicines.